Overview
At a Glance
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate the pituitary gland to produce more growth hormone. It comes in two forms — with and without Drug Affinity Complex (DAC) — which affects its half-life and dosing frequency. It's used in anti-aging and performance circles for body composition and recovery, but clinical data is limited to a handful of small studies. It is not FDA-approved and is sold as a research chemical.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — the natural signal produced by the hypothalamus that tells the pituitary gland to release growth hormone (GH). It consists of the first 29 amino acids of human GHRH with four amino acid substitutions that dramatically increase its resistance to enzymatic degradation, extending its biological half-life from minutes to days (Jetté et al., 2005).
CJC-1295 exists in two primary forms. The original version, CJC-1295 with DAC (Drug Affinity Complex), incorporates a maleimidopropionic acid linker that allows the peptide to bind covalently to serum albumin after injection, extending the effective half-life to approximately 6–8 days. The second form, commonly referred to as CJC-1295 without DAC or "modified GRF 1–29" (mod GRF 1–29), lacks the albumin-binding modification and has a shorter half-life of approximately 30 minutes. Both forms stimulate GH release from the anterior pituitary by binding to the GHRH receptor (Teichman et al., 2006).
In a Phase 2 dose-escalation clinical trial, a single subcutaneous injection of CJC-1295 with DAC produced sustained elevations in GH and insulin-like growth factor I (IGF-1) lasting 6–14 days, with IGF-1 levels increasing by 1.5- to 3-fold above baseline. Multiple weekly doses over 2–3 weeks produced further sustained elevations without significant tachyphylaxis (loss of response) (Teichman et al., 2006).
CJC-1295 without DAC is frequently combined with Ipamorelin, a selective growth hormone secretagogue (GHS) that acts through the ghrelin receptor (GHS-R1a). This combination is intended to amplify pulsatile GH release through two complementary pathways — GHRH receptor activation (CJC-1295) and GHS receptor activation (Ipamorelin) — while maintaining physiological GH pulsatility rather than producing a constant, non-physiological GH elevation (Raun et al., 1998).
CJC-1295 has no FDA-approved indication. It has not completed Phase 3 clinical trials. Clinical use is based on Phase 2 data and provider experience in regenerative and anti-aging medicine settings.
Quick Facts
| Property | Details |
|---|---|
| Molecular formula (no DAC) | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Amino acid sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ |
| Molecular weight (no DAC) | ~3,367 Da |
| Half-life (with DAC) | ~6–8 days (albumin-bound) |
| Half-life (without DAC) | ~30 minutes |
| Route studied | Subcutaneous injection |
| Human trials | Phase 2 completed (dose-escalation); no Phase 3 |
| FDA approval | None |
| WADA status | Prohibited (S2 — peptide hormones, growth factors) |
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
How It Works
GHRH Receptor Activation
Growth hormone secretion from the anterior pituitary is controlled by two opposing hypothalamic signals: GHRH (stimulatory) and somatostatin (inhibitory). CJC-1295 mimics the stimulatory signal by binding to the GHRH receptor (GHRH-R), a G-protein-coupled receptor on pituitary somatotroph cells. Receptor activation triggers intracellular cAMP signaling, leading to GH gene transcription, GH synthesis, and GH vesicle exocytosis (Jetté et al., 2005).
Unlike exogenous GH injection, which delivers a bolus of GH that bypasses the pituitary entirely, CJC-1295 works through the pituitary's existing machinery. This means GH release retains some degree of pulsatility and remains subject to negative feedback from somatostatin and IGF-1. The pituitary's somatotroph cells can only release GH when somatostatin tone is low — CJC-1295 amplifies the peaks of natural GH pulses rather than creating a continuous, flat elevation (Teichman et al., 2006).
DAC vs. No-DAC: The Two Forms
| Feature | CJC-1295 with DAC | CJC-1295 without DAC (mod GRF 1–29) |
|---|---|---|
| Albumin binding | Covalently binds serum albumin via maleimidopropionic acid linker | No albumin binding |
| Half-life | ~6–8 days | ~30 minutes |
| Dosing frequency | 1–2x per week | 1–3x daily |
| GH release pattern | Sustained elevation with blunted pulsatility; continuous GHRH-R stimulation | Acute pulsatile GH release; preserves physiological pulse pattern |
| IGF-1 elevation | 1.5–3x baseline, sustained for days | Transient elevation with each dose |
| Clinical data | Phase 2 trial published (Teichman et al., 2006) | Limited formal trial data; widely used clinically |
| Common pairing | Used alone or with GHRP | Frequently combined with Ipamorelin |
The DAC version produces a longer, more sustained GH/IGF-1 elevation, which simplifies dosing (once or twice per week) but results in a less physiological GH pattern. The no-DAC version requires more frequent dosing but produces sharp, natural-appearing GH pulses that more closely mimic endogenous GH secretion (Jetté et al., 2005).
The CJC-1295 + Ipamorelin Combination
CJC-1295 without DAC is frequently paired with Ipamorelin, a pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a, also known as the ghrelin receptor). The rationale for this combination:
- Complementary receptor pathways: CJC-1295 activates the GHRH receptor while Ipamorelin activates the GHS receptor. These two pathways converge on the somatotroph cell through different intracellular signaling cascades (cAMP for GHRH-R; IP3/DAG for GHS-R), producing a synergistic GH release that exceeds either peptide alone (Raun et al., 1998).
- Selectivity of Ipamorelin: Unlike older GH secretagogues (GHRP-6, GHRP-2), Ipamorelin does not significantly elevate cortisol, ACTH, or prolactin at standard doses. This selectivity makes it a preferred pairing agent (Johansen et al., 1999).
- Preserved pulsatility: Both peptides work through the pituitary rather than bypassing it, so the combined GH release remains pulsatile and subject to somatostatin-mediated negative feedback.
Downstream Effects of GH/IGF-1 Elevation
The physiological effects attributed to CJC-1295 are mediated through the GH/IGF-1 axis. Elevated GH stimulates the liver to produce IGF-1, and both hormones act on target tissues:
- Body composition: GH promotes lipolysis (fat breakdown) and lean mass preservation. IGF-1 supports protein synthesis and muscle maintenance (Rudman et al., 1990).
- Tissue repair: IGF-1 stimulates collagen synthesis, bone formation, and connective tissue repair.
- Sleep architecture: Endogenous GH is primarily secreted during slow-wave (deep) sleep. GHRH administration has been shown to increase slow-wave sleep duration in studies of exogenous GHRH (Steiger et al., 1992).
- Recovery: The GH/IGF-1 axis supports immune function, wound healing, and recovery from physical stress.
Go Deeper
- Teichman et al. (2006) — Phase 2 trial: CJC-1295 pharmacokinetics and GH/IGF-1 response — JCEM
- Jetté et al. (2005) — DAC technology and albumin bioconjugation — Endocrinology
- Raun et al. (1998) — Ipamorelin: selective GH secretagogue — Eur J Endocrinol
- Johansen et al. (1999) — Ipamorelin selectivity and safety — Growth Horm IGF Res
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Research
Phase 2 Clinical Trial: Dose-Escalation Study
The pivotal clinical study for CJC-1295 was a Phase 2 dose-escalation trial conducted in healthy adults. Key findings:
- Design: Single and multiple ascending dose study in healthy volunteers aged 21–61 years. Subcutaneous injection of CJC-1295 with DAC at doses of 30, 60, and 125 mcg/kg.
- GH response: Mean GH levels increased 2- to 10-fold above baseline, with pulsatile secretion maintained. Peak GH response occurred within 2 hours of injection.
- IGF-1 response: IGF-1 levels increased 1.5- to 3-fold and remained elevated for 6–14 days after a single injection. With weekly dosing for 2–3 weeks, IGF-1 remained sustainably elevated.
- Pharmacokinetics: The DAC-albumin bioconjugation extended the half-life to approximately 5.8–8.1 days, enabling once-weekly dosing.
- Tolerability: The peptide was generally well-tolerated. The most common adverse events were injection site reactions, transient flushing, and headache (Teichman et al., 2006).
Pharmacokinetic Profiling
- DAC albumin binding: The Drug Affinity Complex technology was characterized in vitro and in vivo, demonstrating rapid and irreversible covalent binding to serum albumin. This prevented renal clearance and proteolytic degradation, extending the functional half-life by approximately 100-fold compared to native GHRH (Jetté et al., 2005).
- GHRH knockout mouse model: Once-daily CJC-1295 administration normalized growth velocity in GHRH knockout mice, confirming that the analog acts specifically through the GHRH receptor pathway (Alba et al., 2006).
Ipamorelin Clinical Data
While Ipamorelin is a separate compound, its clinical data is relevant because it is the most common pairing agent with CJC-1295 without DAC.
- Selectivity: In healthy volunteers, Ipamorelin produced dose-dependent GH release without significant changes in ACTH, cortisol, prolactin, FSH, LH, or TSH — distinguishing it from less selective secretagogues like GHRP-6 (Raun et al., 1998).
- Safety profile: Ipamorelin showed a favorable side effect profile in clinical studies, with minimal appetite stimulation (unlike ghrelin and GHRP-6) and no significant effect on gastric motility at therapeutic doses (Johansen et al., 1999).
GH/IGF-1 and Body Composition
The rationale for CJC-1295's effects on body composition derives from broader GH physiology research:
- GH in aging adults: The landmark Rudman et al. study demonstrated that exogenous GH administration in men over 60 produced a 14.4% decrease in adipose tissue mass and an 8.8% increase in lean body mass over 6 months (Rudman et al., 1990). CJC-1295 aims to achieve similar GH/IGF-1 elevations through pituitary stimulation rather than direct GH replacement.
- GH secretagogue body composition data: A study of MK-677 (oral GH secretagogue) in healthy older adults showed increased fat-free mass and trends toward improved body composition with sustained GH/IGF-1 elevation over 12 months (Nass et al., 2008). These data are used to support the theoretical framework for CJC-1295's body composition effects, though direct evidence from CJC-1295 body composition trials is lacking.
Sleep Quality and GHRH
- GHRH and slow-wave sleep: Exogenous GHRH administration has been shown to increase the duration and intensity of slow-wave (deep) sleep in clinical studies. The relationship is bidirectional — slow-wave sleep promotes endogenous GH secretion, and GHRH promotes slow-wave sleep (Steiger et al., 1992).
- Age-related GH decline and sleep: The decline in GH secretion with aging parallels the decline in slow-wave sleep duration. Both begin declining in the third decade of life (Van Cauter et al., 2000). This relationship forms the rationale for bedtime dosing of CJC-1295.
Limitations of the Research
- No Phase 3 trials: CJC-1295 has not been evaluated in large, randomized, placebo-controlled Phase 3 studies for any indication.
- Body composition data is extrapolated: Direct evidence for CJC-1295's effect on body composition comes from the GH/IGF-1 elevation data — not from dedicated body composition outcome trials.
- Combination data is limited: The CJC-1295 + Ipamorelin combination has not been evaluated in published controlled trials. Its use is based on the pharmacological rationale of dual-receptor synergy.
- Long-term safety unknown: The longest published exposure data comes from the Phase 2 trial (several weeks). Multi-year safety data does not exist.
- DAC vs. no-DAC comparison: No head-to-head trials compare the two variants for clinical outcomes.
Further Reading
- Teichman et al. (2006) — Phase 2 dose-escalation study — JCEM
- Jetté et al. (2005) — DAC technology characterization — Endocrinology
- Alba et al. (2006) — GHRH knockout mouse model — Am J Physiol
- Rudman et al. (1990) — GH and body composition in aging — NEJM
- Nass et al. (2008) — GH secretagogue and body composition — Ann Intern Med
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Uses
FDA Status
CJC-1295 has no FDA-approved indication. It is not classified as a drug, dietary supplement, or approved biologic product. Any clinical use is experimental within the context of a provider-patient relationship.
How It Has Been Accessed
- Compounding pharmacies (503A/503B): CJC-1295 (often as the CJC-1295/Ipamorelin combination) has been available through licensed compounding pharmacies as a provider-prescribed preparation. Regulatory status has fluctuated (see Regulatory tab).
- Anti-aging and regenerative medicine clinics: Many clinics specializing in hormone optimization prescribe CJC-1295 as part of GH-optimization protocols.
- Research chemical suppliers: CJC-1295 is available as a research chemical sold "not for human consumption." Quality and purity vary between suppliers.
Common Clinical Applications
The following uses are reported in clinical practice. They are based on Phase 2 data, GH physiology research, and provider experience — not FDA-approved indications.
| Application | Evidence Basis | Notes |
|---|---|---|
| Body composition optimization | Phase 2 GH/IGF-1 data; extrapolated from GH physiology studies | Reduction of adipose tissue, preservation or increase of lean mass. Based on the demonstrated GH/IGF-1 elevation and established effects of the GH/IGF-1 axis on fat metabolism and protein synthesis. |
| Anti-aging / age-related GH decline | GH physiology; Phase 2 IGF-1 data | GH secretion declines approximately 14% per decade after age 30. CJC-1295 is used to restore GH/IGF-1 levels toward younger physiological ranges. Effects on skin quality, energy, and overall vitality are reported clinically. |
| Sleep quality improvement | GHRH-sleep relationship studies | GHRH promotes slow-wave sleep. Bedtime dosing of CJC-1295 is used to enhance deep sleep duration and quality. Supported by GHRH-sleep research, not CJC-1295-specific sleep trials. |
| Recovery from exercise or injury | GH/IGF-1 physiology | The GH/IGF-1 axis supports collagen synthesis, tissue repair, and immune function. Used by individuals seeking enhanced recovery from training or injury. |
| Bone density support | GH/IGF-1 physiology | IGF-1 stimulates osteoblast activity. Used adjunctively in individuals with declining bone density, though direct CJC-1295 bone density data is lacking. |
| Immune function support | GH/IGF-1 physiology | GH has documented immunomodulatory effects. Some providers include CJC-1295 in protocols targeting immune resilience. |
The CJC-1295/Ipamorelin Combination in Practice
The most widely used clinical protocol involves CJC-1295 without DAC combined with Ipamorelin, typically administered together as a single subcutaneous injection at bedtime. This combination is preferred because:
- Dual-receptor stimulation (GHRH-R + GHS-R) produces synergistic GH release
- Ipamorelin's selectivity avoids cortisol and prolactin elevation seen with older secretagogues
- Bedtime dosing aligns with the natural nocturnal GH pulse and may enhance slow-wave sleep
- The short half-life of both peptides (without DAC) preserves physiological GH pulsatility
What CJC-1295 Is NOT Used For
- Growth hormone deficiency (as diagnosed condition): FDA-approved recombinant GH (somatropin) is the standard treatment for diagnosed GH deficiency. CJC-1295 is not a substitute for approved GH replacement therapy.
- Direct performance enhancement: CJC-1295 is not an anabolic steroid. While GH/IGF-1 elevation may support recovery, it does not produce the rapid strength or muscle gains associated with anabolic agents.
- Weight loss (as primary agent): While GH promotes lipolysis, CJC-1295 is not used as a standalone weight loss medication.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Dosing
CJC-1295 is not FDA-approved. No official dosing guidelines exist. The information below reflects protocols commonly reported in clinical practice and research literature — it is provided for informational purposes only. Do not self-administer any peptide without guidance from a qualified healthcare provider. Dosing, preparation, and administration should be overseen by a licensed clinician.
Commonly Reported Protocols
| Protocol | Typical Dose | Frequency | Notes |
|---|---|---|---|
| CJC-1295 no DAC alone | 100–300 mcg SC | 1–3x daily (typically at bedtime) | Short half-life (~30 min). Bedtime dosing preferred to coincide with natural nocturnal GH pulse. |
| CJC-1295 no DAC + Ipamorelin | 100–300 mcg CJC + 100–300 mcg Ipa SC | 1x daily at bedtime | Most common clinical protocol. Both peptides administered together in a single injection. Some protocols add a morning dose. |
| CJC-1295 with DAC | 1–2 mg SC | 1–2x per week | Long half-life (~6–8 days). Produces sustained GH/IGF-1 elevation. Less commonly used than the no-DAC/Ipamorelin combination. |
Dosing protocols above are derived from Phase 2 clinical data and reported clinical practice — not from FDA-approved labeling. Key references: Teichman et al., 2006 (JCEM) · Jetté et al., 2005 (Endocrinology) · Raun et al., 1998 (Eur J Endocrinol)
Timing Considerations
- Bedtime dosing: The most common timing. Aligns with the natural nocturnal GH pulse that occurs during slow-wave sleep. GHRH administration at bedtime may enhance slow-wave sleep duration (Steiger et al., 1992).
- Fasted state: GH release is blunted by elevated blood glucose and insulin. Providers typically recommend dosing at least 2 hours after the last meal or carbohydrate intake.
- Morning dosing (optional second dose): Some protocols include a morning dose upon waking (fasted) in addition to bedtime dosing, to amplify the morning cortisol-associated GH pulse.
Cycling Patterns
No established evidence base exists for optimal treatment duration or cycling. Common clinical patterns:
- Standard cycle: 8–12 weeks on, 4 weeks off
- Extended protocol: 3–6 months continuous use with periodic IGF-1 monitoring
- 5-days-on, 2-days-off: Some providers recommend weekday dosing with weekend breaks to prevent receptor desensitization, though evidence for this approach is theoretical
Monitoring
Providers prescribing CJC-1295 typically monitor:
- IGF-1 levels: Primary biomarker. Target range varies by provider philosophy — some aim for upper-normal age-adjusted range, others target levels associated with younger physiology.
- Fasting glucose and HbA1c: GH can impair insulin sensitivity. Periodic glucose monitoring is standard.
- Complete blood count: Baseline and periodic monitoring.
- Thyroid function: GH can affect T4-to-T3 conversion.
Administration Guidance
CJC-1295 for subcutaneous use is typically supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. Preparation and administration technique should be demonstrated and supervised by your prescribing healthcare provider or pharmacist.
Storage
- Lyophilized powder: Store refrigerated (2–8°C / 36–46°F). Stable for months when kept dry and cold.
- Reconstituted solution: Refrigerate and use within 3–4 weeks. Do not freeze. Discard if solution becomes cloudy or discolored.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Results: What Users Report
The following timeline is compiled from clinician reports, patient surveys, and online communities — not from randomized controlled trials. Individual experiences vary significantly. CJC-1295 has not been evaluated for efficacy in Phase 3 human trials for any of the outcomes described below.
Reported Timeline
| Timepoint | What Users Typically Report |
|---|---|
| Days 1–7 | Improved sleep onset and depth. Vivid dreams. Some users report feeling more rested upon waking. Mild flushing or warmth after injection (transient, resolves in minutes). |
| Week 2–4 | Consistent sleep quality improvement. Increased energy and recovery from exercise. Some users report improved skin hydration and texture. Early body composition changes may begin (reduced water retention, subtle fat loss). |
| Week 4–8 | More noticeable body composition changes: reduced abdominal adiposity, improved muscle tone. Enhanced recovery from training. Users report improved nail and hair quality. IGF-1 blood levels typically show measurable elevation by this point. |
| Week 8–12 | Body composition changes become more pronounced with consistent use and appropriate diet/exercise. Some users report joint comfort improvement (attributed to IGF-1-mediated collagen synthesis). Skin quality improvements continue. |
| Month 3–6 | Plateau for most effects. Users on extended protocols report sustained improvements in energy, body composition, and recovery. Providers typically reassess IGF-1 levels and adjust dosing. |
Sleep-Related Reports
Sleep improvement is one of the most consistently reported early effects. Users describe:
- Faster sleep onset after bedtime dosing
- Deeper, more restorative sleep (consistent with GHRH's effect on slow-wave sleep)
- More vivid dreaming (possibly related to increased slow-wave sleep duration)
- Feeling more refreshed upon waking
- Improved sleep continuity (fewer nighttime awakenings)
Body Composition Reports
Users focused on body composition changes describe:
- Gradual reduction in abdominal and visceral fat over 4–12 weeks
- Improved muscle definition, particularly when combined with resistance training
- Subtle changes in body weight (may decrease, stay stable, or slightly increase depending on fat loss vs. lean mass gain)
- Changes are gradual and modest compared to exogenous GH administration at pharmacological doses
Contextualizing These Reports
- Placebo effect: Sleep improvement and subjective energy changes are particularly susceptible to placebo response. Without controlled data, the contribution of expectation cannot be separated from pharmacological effect.
- Concurrent lifestyle factors: Many users initiating CJC-1295 simultaneously improve diet, exercise, and sleep habits as part of an optimization protocol, confounding attribution.
- Selection bias: Positive experiences are disproportionately shared in online communities.
- Objective biomarker: IGF-1 elevation is objectively measurable and consistently documented in clinical settings, confirming biological activity. Translation of IGF-1 elevation to clinical outcomes is supported by GH physiology but not by CJC-1295-specific outcome trials.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Side Effects
Reported Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Flushing / warmth | Common | Transient facial flushing or sensation of warmth shortly after injection. Typically resolves within 10–30 minutes. Related to vasodilation. |
| Headache | Common | Mild to moderate, typically occurring in the first 1–2 weeks of use and diminishing with continued dosing. |
| Water retention | Common | Mild peripheral edema (particularly in hands and feet). Related to GH's sodium- and water-retaining effects. Dose-dependent. |
| Injection site reactions | Common | Mild redness, swelling, or tenderness at the injection site. Typically resolves within hours. |
| Tingling / numbness | Uncommon | Paresthesias in hands or fingers, related to GH-mediated fluid shifts. Often described as carpal tunnel-like symptoms. Dose-dependent and typically reversible. |
| Dizziness / lightheadedness | Uncommon | May occur shortly after injection, possibly related to transient blood pressure changes. |
| Increased hunger | Uncommon | More commonly reported when combined with less selective GH secretagogues (GHRP-6). Less common with CJC-1295/Ipamorelin specifically. |
| Joint stiffness | Uncommon | Typically at higher doses or with sustained elevated IGF-1. Related to GH effects on connective tissue hydration. |
Note: Frequency estimates are based on Phase 2 trial data and clinical reports. True population-level incidence rates have not been established through Phase 3 trials (Teichman et al., 2006).
Hormonal Considerations
- Cortisol: CJC-1295 alone (as a GHRH analog) has minimal direct effect on cortisol secretion. However, some GH secretagogues (GHRP-6, hexarelin) can stimulate ACTH and cortisol release. Ipamorelin is preferred as a pairing agent specifically because it does not significantly affect cortisol (Johansen et al., 1999).
- Prolactin: Similar to cortisol, prolactin elevation is primarily a concern with less selective secretagogues. Ipamorelin does not significantly elevate prolactin at standard doses. CJC-1295 alone does not directly stimulate prolactin.
- Insulin sensitivity: GH is a counter-regulatory hormone that promotes insulin resistance. Sustained GH/IGF-1 elevation from CJC-1295 may impair glucose tolerance, particularly at higher doses or with prolonged use. Fasting glucose and HbA1c monitoring is recommended (Sackmann-Sala et al., 2009).
- Thyroid: GH can increase the conversion of T4 to T3, potentially unmasking subclinical hypothyroidism in individuals with borderline thyroid function.
Theoretical Risks and Concerns
- GH and cancer risk: Elevated IGF-1 has been associated with increased risk of certain cancers (colorectal, prostate, breast) in epidemiological studies. The clinical significance of CJC-1295-induced IGF-1 elevation within or slightly above the physiological range is unknown, but individuals with active malignancies or strong cancer predisposition should exercise caution.
- Acromegaly-like effects: Chronic supraphysiological GH/IGF-1 elevation can produce acromegaly-like features (soft tissue swelling, joint enlargement, insulin resistance). This is a concern primarily at excessive doses or with unmonitored long-term use.
- Long-term safety: No multi-year safety data exists for CJC-1295 in humans.
Drug Interactions
- Diabetes medications / insulin: GH impairs insulin sensitivity. Individuals on glucose-lowering medications may need dose adjustments.
- Corticosteroids: Both GH and corticosteroids affect glucose metabolism. Combined use warrants monitoring.
- Thyroid medications: GH may alter thyroid hormone metabolism. Thyroid function should be monitored, particularly in individuals on levothyroxine.
Contraindications
- Active cancer or recent cancer history — due to IGF-1's role in cell proliferation
- Pregnancy and breastfeeding — no safety data available
- Active diabetic retinopathy — GH can worsen retinopathy
- Uncontrolled diabetes — GH impairs insulin sensitivity
- Children — no pediatric data available for CJC-1295
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Regulatory Status
FDA Classification
| Status | Action | Impact |
|---|---|---|
| Pre-2024 | Available as compounding ingredient | Widely available through 503A and 503B compounding pharmacies. No specific FDA prohibition on compounding. |
| 2024 | FDA bulk substance review | CJC-1295 was included in the FDA's evaluation of bulk drug substances used in compounding. Regulatory uncertainty increased. |
| Proposed | Potential return to Category 1 | The FDA's evolving framework for peptide compounding may reclassify CJC-1295 as suitable for compounding (Category 1). This would restore compounding pharmacy access under standard prescribing and compounding regulations. The reclassification process is ongoing. |
Understanding the FDA Categories
- Category 1: May be used in compounding — sufficient data on safety, identity, and historical use.
- Category 2: Not suitable for compounding — insufficient safety data or specific concerns identified.
- Category 3: Under evaluation — more data needed.
Category classification pertains specifically to compounding pharmacy use. It does not make a substance a controlled or scheduled drug. CJC-1295 is not a DEA-scheduled substance.
WADA Prohibited Status
WADA lists CJC-1295 as a prohibited substance under Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. This category includes:
- Growth hormone-releasing hormones (GHRH) and their analogs — which directly covers CJC-1295
- Growth hormone secretagogues — which covers Ipamorelin and related compounds
- Growth hormone (GH) itself and IGF-1
CJC-1295 is prohibited at all times (in-competition and out-of-competition). Detection methods for synthetic GHRH analogs have been developed and are in use. Athletes subject to WADA testing should be aware that CJC-1295 and Ipamorelin are both detectable and prohibited.
Research Chemical Market
CJC-1295 remains widely available through research chemical suppliers, typically labeled "for research purposes only." The same quality and purity concerns that apply to other peptides in this market apply here:
- No requirement for cGMP manufacturing standards
- Variable purity and potency between suppliers
- Some suppliers provide certificates of analysis (COAs); independent verification is not standard
- Products are not intended or labeled for human use
International Status
CJC-1295 is not approved as a therapeutic agent in any major regulatory jurisdiction (FDA, EMA, MHRA, TGA). Regulatory treatment varies by country. Some jurisdictions have more permissive frameworks for peptide therapies within provider-patient relationships.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Cost
Typical Pricing
| Source | Typical Price Range | What You Get | Quality Assurance |
|---|---|---|---|
| Compounding pharmacy (503A) | $200–$400/month | Patient-specific CJC-1295/Ipamorelin combination, lyophilized vial, prescribed by provider. | Highest — regulated pharmacy, USP standards, prescription required. |
| Compounding pharmacy (503B) | $175–$350/month | Outsourcing facility production. Often supplied to clinics in bulk. | High — FDA-registered, cGMP-adjacent, batch tested. |
| Anti-aging clinic (bundled) | $250–$500/month | Peptide supply plus provider oversight, lab monitoring, and consultation. Pricing varies widely by clinic. | Variable — depends on pharmacy source. Ask about sourcing. |
| Research chemical supplier | $40–$120/month | Lyophilized powder, labeled "for research only." Buyer reconstitutes independently. | Variable — some provide COAs; quality inconsistent across suppliers. |
Insurance Coverage
CJC-1295 is not covered by any insurance plan. It has no FDA-approved indication and cannot be billed under any drug or medical benefit. All costs are out-of-pocket. Lab monitoring (IGF-1, glucose, etc.) may be partially covered depending on how it is coded and the specific insurance plan.
Factors Affecting Cost
- Combination vs. single agent: CJC-1295/Ipamorelin combination vials are the standard clinical product. Purchasing the peptides separately from research suppliers may be less expensive but introduces additional preparation complexity and quality risk.
- Dosing protocol: Higher doses or twice-daily protocols consume vials faster, increasing monthly cost.
- DAC vs. no-DAC: The DAC variant requires fewer injections per week, but the per-vial cost may be higher. Monthly costs are roughly comparable between the two forms.
- Provider and monitoring fees: Many clinics charge initial consultation fees ($150–$400) and periodic lab monitoring fees ($100–$300 per panel) in addition to peptide cost.
- Regulatory status and supply: Disruptions to compounding pharmacy access affect pricing. Periods of restricted supply tend to increase costs across all channels.
Cost Comparison: CJC-1295 vs. Related Treatments
| Treatment | Typical Monthly Cost | Insurance |
|---|---|---|
| CJC-1295/Ipamorelin (compounding) | $200–$400 | Not covered |
| CJC-1295/Ipamorelin (research chemical) | $40–$120 | Not covered |
| Recombinant GH (somatropin) — prescribed | $800–$3,000+ | Covered if diagnosed GH deficiency |
| Sermorelin (GHRH analog) | $200–$500 | Rarely covered |
| MK-677 (oral GH secretagogue) | $50–$150 | Not covered |
| Tesamorelin (FDA-approved GHRH analog) | $1,000–$1,500 | Covered for HIV lipodystrophy only |
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Questions & Answers
Myth: CJC-1295 is the same as taking growth hormone.
Answer: CJC-1295 is a GHRH analog that stimulates the pituitary to release its own GH. Exogenous GH (somatropin) bypasses the pituitary entirely, delivering a bolus of synthetic GH directly into the bloodstream. Key differences: CJC-1295 preserves pulsatile GH secretion and maintains negative feedback loops (somatostatin, IGF-1), while exogenous GH produces supraphysiological peaks and can suppress endogenous GH production. CJC-1295 produces more modest GH/IGF-1 elevations than pharmacological doses of exogenous GH (Teichman et al., 2006).
Myth: CJC-1295 will make you huge.
Answer: CJC-1295 is not an anabolic steroid and does not directly stimulate muscle protein synthesis the way testosterone or other androgens do. The GH/IGF-1 elevation it produces supports body composition improvement (fat loss, lean mass preservation) and recovery, but the magnitude of change is modest compared to anabolic agents or pharmacological-dose GH. Significant muscle growth requires resistance training and adequate nutrition regardless of GH status.
Myth: DAC and no-DAC are interchangeable.
Answer: The two forms have fundamentally different pharmacokinetics. CJC-1295 with DAC has a half-life of 6–8 days and produces sustained, continuous GHRH receptor stimulation. CJC-1295 without DAC has a half-life of approximately 30 minutes and produces acute, pulsatile GH release. The no-DAC version more closely mimics natural GH secretion patterns. The choice between them involves different dosing frequencies, different GH release profiles, and potentially different clinical outcomes — though no head-to-head comparison trial has been published (Jetté et al., 2005).
Myth: CJC-1295 is FDA approved for anti-aging.
Answer: CJC-1295 has no FDA approval for any indication, including anti-aging, body composition, or GH optimization. "Anti-aging" is not an FDA-recognized disease category. The only GHRH analog with FDA approval is tesamorelin (Egrifta), and that approval is limited to HIV-associated lipodystrophy — not general anti-aging use.
Myth: You don't need a doctor for peptides.
Answer: While CJC-1295 is accessible through research chemical suppliers without a prescription, clinical use involves hormonal manipulation of the GH/IGF-1 axis — a system that affects glucose metabolism, cancer risk, thyroid function, and multiple organ systems. Appropriate use includes baseline and periodic lab monitoring (IGF-1, glucose, thyroid), contraindication screening (cancer history, diabetes), and dose adjustment based on biomarkers. Unsupervised use carries risks that may not be apparent without monitoring.
Myth: CJC-1295 causes cancer.
Answer: There is no direct evidence that CJC-1295 causes cancer. The concern is based on epidemiological associations between elevated IGF-1 levels and increased risk of certain cancers (particularly colorectal and prostate). This association is observed in population studies of endogenous IGF-1 variability — not in studies of CJC-1295 specifically. The clinical significance of CJC-1295-induced IGF-1 elevation within or modestly above the physiological range is unknown. Individuals with active malignancies should avoid GH-elevating therapies as a precaution.
Myth: All peptide suppliers are the same.
Answer: Product quality varies enormously. Compounding pharmacies operate under regulatory oversight with USP standards for identity, potency, and purity. Research chemical suppliers have no such requirements. Independent testing has documented significant variability in peptide content, with some research products containing substantially less active peptide than labeled, degradation products, or contaminants. Source and quality verification matter.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Key Takeaways
Based on the available evidence:
- CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to release growth hormone in a pulsatile pattern. It exists in two forms: with DAC (long-acting, weekly dosing) and without DAC (short-acting, daily dosing, commonly paired with Ipamorelin).
- Phase 2 clinical data demonstrates sustained GH and IGF-1 elevation (1.5–3x baseline) lasting days to weeks. The peptide was generally well-tolerated in trial participants (Teichman et al., 2006).
- It is not FDA-approved for any indication. Clinical use is based on Phase 2 data, GH physiology research, and provider experience in anti-aging and regenerative medicine settings.
- Common clinical applications include body composition optimization, sleep quality improvement, recovery enhancement, and age-related GH decline — all based on the GH/IGF-1 axis effects rather than indication-specific trials.
- The CJC-1295/Ipamorelin combination is the most widely used clinical protocol, leveraging dual-receptor synergy (GHRH-R + GHS-R) while maintaining GH pulsatility and avoiding cortisol/prolactin elevation.
- Side effects are generally mild: flushing, headache, water retention, and injection site reactions. Potential concerns include effects on insulin sensitivity and the theoretical relationship between IGF-1 elevation and cancer risk.
- Regulatory status is evolving. CJC-1295 may return to Category 1 (suitable for compounding) under the FDA's ongoing reclassification process. It is prohibited by WADA.
- Cost ranges from $150–$400/month through compounding pharmacies, with no insurance coverage.
- Product quality varies significantly between compounding pharmacies and research chemical suppliers. Source verification is important.
Who Might Consider CJC-1295
Based on available evidence and clinical practice, CJC-1295 may be worth discussing with a healthcare provider for individuals who:
- Are experiencing age-related decline in GH/IGF-1 (documented by lab testing)
- Seek body composition improvement (fat reduction, lean mass preservation) alongside appropriate diet and exercise
- Report poor sleep quality, particularly reduced deep sleep
- Are recovering from injury or seeking enhanced recovery from physical training
- Have access to a knowledgeable provider who can prescribe, monitor labs, and adjust dosing
- Understand that evidence is limited to Phase 2 data and accept the associated uncertainty
Questions to Ask a Provider
- Based on my lab values and health history, is CJC-1295 appropriate for me?
- Do you recommend the DAC or no-DAC version, and with or without Ipamorelin?
- What dosing protocol and duration do you recommend?
- What lab monitoring will you perform, and how often?
- Where will the peptide be sourced, and what quality testing has been performed?
- What are realistic expectations for my specific goals?
- Are there interactions with my current medications?
- Given my cancer history / diabetes / other conditions — is this appropriate?
- What is the current regulatory status and its implications for prescribing?
This content is for informational and educational purposes only. It is not intended as, and should not be interpreted as, medical advice. The information provided does not cover all possible uses, precautions, interactions, or adverse effects, and may not reflect the most recent medical research or guidelines. It should not be used as a substitute for the advice of a qualified healthcare professional. Never disregard professional medical advice or delay seeking treatment because of something you have read here. Always speak with your doctor or pharmacist before starting, stopping, or changing any prescribed medication or treatment. If you think you may have a medical emergency, call your doctor or emergency services immediately. GLPbase does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Use of this information is at your own risk.
Sources & Further Reading
CJC-1295 Clinical & Pharmacokinetic Studies
- Teichman SL et al. (2006) — "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults" — Journal of Clinical Endocrinology & Metabolism
- Jetté L et al. (2005) — "hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog" — Endocrinology
- Alba M et al. (2006) — "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout (GHRHKO) mouse" — American Journal of Physiology: Endocrinology and Metabolism
Ipamorelin & GH Secretagogues
- Raun K et al. (1998) — "Ipamorelin, the first selective growth hormone secretagogue" — European Journal of Endocrinology
- Johansen PB et al. (1999) — "Ipamorelin, a new growth-hormone-releasing peptide, induces growth hormone secretion in beagles by stimulating the growth hormone secretagogue receptor" — Growth Hormone & IGF Research
- Nass R et al. (2008) — "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial" — Annals of Internal Medicine
Growth Hormone Physiology & Body Composition
- Rudman D et al. (1990) — "Effects of human growth hormone in men over 60 years old" — New England Journal of Medicine
- Sackmann-Sala L et al. (2009) — "Drug insight: the growth hormone receptor and its signal transduction pathways" — Nature Clinical Practice Endocrinology & Metabolism
Sleep & GHRH
- Steiger A et al. (1992) — "Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls" — Neuroendocrinology
- Van Cauter E et al. (2000) — "Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men" — JAMA
Regulatory & Classification
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
